Aduhelm

Biogen offered a window into what’s holding up Aduhelm. Investors didn’t like what they saw.
Health

Biogen offered a window into what’s holding up Aduhelm. Investors didn’t like what they saw.

Biogen executives mentioned Thursday that the launch of the corporate’s extremely anticipated drug for Alzheimer’s illness is not going as…
Back to top button
close